Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma
This multi-center randomized controlled phase II trial will investigate the impact of
stereotactic fractionated radiotherapy to the resection cavity of complete resected recurrent
glioblastoma on progression free survival. As secondary endpoints, overall survival, safety
and toxicity as well as early response criteria on MRI, quality of life and neurocognitive
function will be assessed. Chemotherapy will not be part of the protocol, however, additional
treatment will be possible upon investigators best choice.